GeneFab and RegCell Announce Strategic Partnership to Advance Autoimmune Cell Therapy into U.S. Clinical Trials

GeneFab, a next-generation cell and gene therapy-focused contract research, development, and manufacturing organization (CRDMO), has partnered with RegCell, a biotech company advancing regulatory T cell (Treg) therapies for autoimmune diseases.

GeneFab Appoints Vadim Eristavi as Head of Quality to Bolster Commercial Readiness for Manufacturing of Cell and Gene Therapies

GeneFab is pleased to announce the appointment of Vadim Eristavi as its new Vice President of Quality. Bringing over 25 years of extensive experience in the biopharmaceutical industry, Vadim will oversee the Quality Assurance and Quality Control teams at GeneFab.

Senti Bio Announces Phase 1 Clinical Trial of SENTI-202

Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

GeneFab Announces Two Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2024

GeneFab, LLC (“GeneFab”), an expert contract research, development and manufacturing organization (CRDMO) today announced two poster presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, which will be held May 7 to 11, 2024 in Baltimore, MD.

Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting

In collaboration with GeneFab, Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting

GeneFab Launches new cGMP facility in Alameda

GeneFab’s cGMP facility in the San Francisco Bay Area has available capacity to support new customers with complex cell and gene therapy manufacturing.